by swisschambei in Engineering / Manufacturing
Novartis pledges to continue pushing innovation in China with new treatments and solutions in the cardiovascular sector, one of the most common diseases in China. Novartis’ major lipid-lowering drug “Inclisiran” is a key exhibit at the Swiss pharma giant’s presence during the 4th China International Import Expo. Johan Kahlstroem, senior vice president and business unit head of Cardiovascular, Renal & Metabolism at Novartis Pharma (China), said it aims to continue to strengthen partnerships with local stakeholders and to raise the overall treatment levels for cardiovascular diseases. Novartis is fully engaged in the Chinese market from manufacturing to business development, covering the whole industry value chain. It has been committed to offering innovative solutions and partnerships that could be valuable in achieving the goals of Healthy China 2030. The increasing prevalence of cardiovascular disease is a serious burden for patients and their families, and it’s also a huge challenge for healthcare provision and health budgets. According to the Chinese Cardiovascular Association, it’s estimated that there were about 330 million cardiovascular disease patients in China in 2019, about a quarter of the population, and it was responsible for 43% of deaths that year.